about
Possible mitochondrial dysfunction and its association with antiretroviral therapy use in children perinatally infected with HIVPrenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy.Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C.Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.Mode of delivery and infant respiratory morbidity among infants born to HIV-1-infected womenCorrelates of human papillomavirus vaccination rates in low-income, minority adolescents: a multicenter studySubstance use in HIV-Infected women during pregnancy: self-report versus meconium analysis.Short communication: transplacental nucleoside analogue exposure and mitochondrial parameters in HIV-uninfected childrenPotential confounding of the association between exposure to nucleoside analogues and mitochondrial dysfunction in HIV-uninfected and indeterminate infants.In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children.Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure.Towards more effective public health programming for injection drug users: development and evaluation of the injection drug user quality of life scale.Human immunodeficiency virus diagnostic testing of infants at clinical sites in North America: 2002-2006.Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.Malignancy in perinatally human immunodeficiency virus-infected children in the United States.Participation of HIV-infected pregnant women in research in the United States.Intensity of drug injection as a determinant of sustained injection cessation among chronic drug users: the interface with social factors and service utilization.In utero nucleoside reverse transcriptase inhibitor exposure and cancer in HIV-uninfected children: an update from the pediatric AIDS clinical trials group 219 and 219C cohorts.Reproductive health of adolescent girls perinatally infected with HIVHIV-Positive Notification and Behavior Changes in Montreal Injection Drug UsersRisk behaviour change and HIV infection among injection drug users in MontrealAntiretroviral Treatment in Pediatric HIV Infection in the United States From Clinical Trials to Clinical PracticeSatellite Needle Distribution Among Injection Drug Users: Policy and Practice in Two Canadian CitiesEpidemiology research
P50
Q34036150-2D7F854B-DA03-41B0-B022-FA9CD71C2D0CQ34158407-74DE9139-CDC3-4A32-94DE-308B7F765EA3Q34170220-E26CCB9B-FB1F-40C3-8005-B075651BA753Q34181048-7FCBDBF7-E447-4B13-BFCA-66419023CD05Q34240876-35467759-0174-488B-8F33-0B0FDEA89B2EQ34365197-E292B4CA-D0F6-43E3-91F1-8F34196B52F9Q34992602-0ED82164-4FCD-49B1-B6F6-9C01A14A229FQ35173620-E28487D6-7B8F-4C2D-A173-08ABEA1D381AQ35620778-16A030D6-A0A2-41D6-91AF-2E0698D90DDCQ36800856-FF1922E1-21D9-4771-80AC-4CD7E332C471Q37439907-DC60DFAD-C3BF-4B30-86B7-59A146256E56Q44474511-A4ABF040-1454-4E62-B0ED-42226A372A2DQ45384088-63F7FA51-0A1F-40D7-B859-821F4BCE9157Q45413646-3DB7352B-167E-455E-A40A-38CFA5D14ED8Q45503440-7DE7FCD4-305D-4479-B52E-D66D2A2335D6Q46572560-5E9FD34A-B825-4D25-A11A-397E8EECB141Q50147502-92F7F80B-B4FA-43CD-9A1F-27FAA3E4C0EDQ51942604-FE10ABAD-7E58-422D-801E-EDDFEB33EADCQ57089404-F9474904-77C8-4EBB-AA80-12675D14695BQ57089446-34BC1DC4-A49D-4BE0-9D31-BC85CA9F075AQ57089465-06C610B8-9819-489A-B60B-6185A8358DEEQ58285674-E6B49932-0E16-4376-8391-51A87157C39AQ61440994-32292225-C46E-405A-8197-0FA59BC93A64Q61440996-B65F7536-4E8E-4794-AC08-F7AB407C0171
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Susan Brogly
@ast
Susan Brogly
@en
Susan Brogly
@es
Susan Brogly
@nl
Susan Brogly
@sl
type
label
Susan Brogly
@ast
Susan Brogly
@en
Susan Brogly
@es
Susan Brogly
@nl
Susan Brogly
@sl
prefLabel
Susan Brogly
@ast
Susan Brogly
@en
Susan Brogly
@es
Susan Brogly
@nl
Susan Brogly
@sl
P106
P21
P31
P496
0000-0002-2339-3287